Marshall Wace’s Compass Therapeutics CMPX Stock Holding History

Marshall Wace’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$733K	Buy	+334,869	New	+$989K	﹤0.01%	2344
2026 Q1	–	Sell	-1,263,647	Closed	-$6.79M	–	3259
2025 Q4	$6.79M	Buy	+1,263,647	New	+$5.84M	0.01%	1022
2023 Q2	–	Sell	-65,177	Closed	-$213K	–	2527
2023 Q1	$213K	Buy	65,177 +36,881	+130%	+$145K	﹤0.01%	2400
2022 Q4	$142K	Sell	28,296 -23,520	-45%	-$93.8K	﹤0.01%	2747
2022 Q3	$117K	Buy	51,816 +28,089	+118%	+$77.8K	﹤0.01%	3169
2022 Q2	$63K	Buy	+23,727	New	+$51.5K	﹤0.01%	3315

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's CMPX Position: Q2 2026 in Review

Marshall Wace opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 334,869 shares worth $733K. The stake represents ﹤0.01% of the portfolio and ranks #2344 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CMPX as recently as Q4 2025.

Marshall Wace first reported a position in CMPX in Q2 2022 and has held it in 6 quarters since. The position peaked at $6.79M in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

Marshall Wace held 334,869 shares of Compass Therapeutics worth $733K as of Q2 2026.
Compass Therapeutics was a new Marshall Wace position in Q2 2026.
Compass Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2344 holding.
Marshall Wace first reported a position in Compass Therapeutics in Q2 2022 and has held it in 6 quarters since.
Marshall Wace's Compass Therapeutics position peaked at $6.79M in Q4 2025.
216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.